Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Anti-inflammatory Drug Combination Therapy for Atherosclerosis: Colchicine and Fenofibrate

Author(s): Michael Spartalis*, Ioanna Tzima, Artemis Anastasiou, Eleftherios Spartalis, Dimitrios C. Iliopoulos and Gerasimos Siasos

Volume 29, Issue 26, 2022

Published on: 17 May, 2022

Page: [4477 - 4480] Pages: 4

DOI: 10.2174/0929867329666220407095216

« Previous Next »
[1]
Imazio, M.; Nidorf, M. Colchicine and the heart. Eur. Heart J., 2021, 42(28), 2745-2760.
[http://dx.doi.org/10.1093/eurheartj/ehab221] [PMID: 33961006]
[2]
Kaminiotis, V.V.; Agrogiannis, G.; Konstantopoulos, P.; Androutsopoulou, V.; Korou, L.M.; Vlachos, I.S.; Dontas, I.A.; Perrea, D.; Iliopoulos, D.C. Per os colchicine administration in cholesterol fed rab-bits: Triglycerides lowering effects without affecting atherosclerosis progress. Lipids Health Dis., 2017, 16(1), 184.
[http://dx.doi.org/10.1186/s12944-017-0573-8] [PMID: 28950870]
[3]
Spartalis, M.; Siasos, G.; Mastrogeorgiou, M.; Spartalis, E.; Kaminiotis, V.V.; Mylonas, K.S.; Kapel-ouzou, A.; Kontogiannis, C.; Doulamis, I.P.; Toutouzas, K.; Nikiteas, N.; Iliopoulos, D.C. The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglycer-ide levels and the development of atherosclerotic lesions in cholesterol-fed rabbits. Eur. Rev. Med. Pharmacol. Sci., 2021, 25(24), 7765-7776.
[PMID: 34982438]
[4]
Mylonas, K.S.; Kapelouzou, A.; Spartalis, M.; Mastrogeorgiou, M.; Spartalis, E.; Bakoyiannis, C.; Liakakos, T.; Schizas, D.; Iliopoulos, D.; Nikiteas, N. KLF4 upregulation in atherosclerotic thoracic aortas: Exploring the protective effect of colchicine-based regimens in a hyperlipidemic rabbit model. Ann. Vasc. Surg., 2022, 78, 328-335.
[http://dx.doi.org/10.1016/j.avsg.2021.04.040] [PMID: 34182114]
[5]
Spartalis, M.; Spartalis, E.; Tzatzaki, E.; Tsilimigras, D.I.; Moris, D.; Kontogiannis, C.; Kaminiotis, V.V.; Paschou, S.A.; Chatzidou, S.; Siasos, G.; Voudris, V.; Iliopoulos, D.C. The beneficial therapy with colchicine for atherosclerosis via anti-inflammation and decrease in hypertriglyceridemia. Cardiovasc. Hematol. Agents Med. Chem., 2018, 16(2), 74-80.
[http://dx.doi.org/10.2174/1871525717666181211110332] [PMID: 30526472]
[6]
Nidorf, S.M.; Eikelboom, J.W.; Budgeon, C.A.; Thompson, P.L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol., 2013, 61(4), 404-410.
[http://dx.doi.org/10.1016/j.jacc.2012.10.027] [PMID: 23265346]
[7]
Martínez, G.J.; Robertson, S.; Barraclough, J.; Xia, Q.; Mallat, Z.; Bursill, C.; Celermajer, D.S.; Patel, S. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J. Am. Heart Assoc., 2015, 4(8), e002128.
[http://dx.doi.org/10.1161/JAHA.115.002128] [PMID: 26304941]
[8]
Misawa, T.; Takahama, M.; Kozaki, T.; Lee, H.; Zou, J.; Saitoh, T.; Akira, S. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat. Immunol., 2013, 14(5), 454-460.
[http://dx.doi.org/10.1038/ni.2550] [PMID: 23502856]
[9]
Slobodnick, A.; Shah, B.; Pillinger, M.H.; Krasnokutsky, S. Colchicine: Old and new. Am. J. Med., 2015, 128(5), 461-470.
[http://dx.doi.org/10.1016/j.amjmed.2014.12.010] [PMID: 25554368]
[10]
Yamagami, H.; Kitagawa, K.; Hoshi, T.; Furukado, S.; Hougaku, H.; Nagai, Y.; Hori, M. Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler. Thromb. Vasc. Biol., 2005, 25(7), 1458-1462.
[http://dx.doi.org/10.1161/01.ATV.0000168417.52486.56] [PMID: 15860738]
[11]
Whitman, S.C.; Ravisankar, P.; Daugherty, A. Interleukin-18 enhances atherosclerosis in apolipopro-tein E(-/-) mice through release of interferon-γ. Circ. Res., 2002, 90(2), E34-E38.
[http://dx.doi.org/10.1161/hh0202.105292] [PMID: 11834721]
[12]
Blankenberg, S.; Tiret, L.; Bickel, C.; Peetz, D.; Cambien, F.; Meyer, J.; Rupprecht, H.J. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation, 2002, 106(1), 24-30.
[http://dx.doi.org/10.1161/01.CIR.0000020546.30940.92] [PMID: 12093765]
[13]
Mallat, Z.; Corbaz, A.; Scoazec, A.; Graber, P.; Alouani, S.; Esposito, B.; Humbert, Y.; Chvatchko, Y.; Tedgui, A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ. Res., 2001, 89(7), E41-E45.
[http://dx.doi.org/10.1161/hh1901.098735] [PMID: 11577031]
[14]
Pope, R.M.; Tschopp, J. The role of interleukin-1 and the inflammasome in gout: Implications for therapy. Arthritis Rheum., 2007, 56(10), 3183-3188.
[http://dx.doi.org/10.1002/art.22938] [PMID: 17907163]
[15]
Robertson, S.; Martínez, G.J.; Payet, C.A.; Barraclough, J.Y.; Celermajer, D.S.; Bursill, C.; Patel, S. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflam-masome monocyte activation. Clin. Sci. (Lond.), 2016, 130(14), 1237-1246.
[http://dx.doi.org/10.1042/CS20160090] [PMID: 27129183]
[16]
Menu, P.; Pellegrin, M.; Aubert, J.F.; Bouzourene, K.; Tardivel, A.; Mazzolai, L.; Tschopp, J. Athero-sclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis., 2011, 2(3), e137.
[http://dx.doi.org/10.1038/cddis.2011.18] [PMID: 21451572]
[17]
Blankenberg, S.; Luc, G.; Ducimetière, P.; Arveiler, D.; Ferrières, J.; Amouyel, P.; Evans, A.; Cambi-en, F.; Tiret, L. Interleukin-18 and the risk of coronary heart disease in European men: The Prospec-tive Epidemiological Study of Myocardial Infarction (PRIME). Circulation, 2003, 108(20), 2453-2459.
[http://dx.doi.org/10.1161/01.CIR.0000099509.76044.A2] [PMID: 14581397]
[18]
Duez, H.; Chao, Y.S.; Hernandez, M.; Torpier, G.; Poulain, P.; Mundt, S.; Mallat, Z.; Teissier, E.; Burton, C.A.; Tedgui, A.; Fruchart, J.C.; Fiévet, C.; Wright, S.D.; Staels, B. Reduction of atheroscle-rosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J. Biol. Chem., 2002, 277(50), 48051-48057.
[http://dx.doi.org/10.1074/jbc.M206966200] [PMID: 12377786]
[19]
Prasad, G.S.; Govardhan, P.; Deepika, G.; Vakdevi, V.; Sashidhar, R.B. Anti-inflammatory activity of anti-hyperlipidemic drug, fenofibrate, and its phase-I metabolite fenofibric acid: In silico, in vitro, and in vivo studies. Inflammopharmacology, 2018, 26(4), 973-981.
[http://dx.doi.org/10.1007/s10787-017-0428-y] [PMID: 29238904]
[20]
Jakob, T.; Nordmann, A.J.; Schandelmaier, S.; Ferreira-González, I.; Briel, M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst. Rev., 2016, 11(3), CD009753.
[http://dx.doi.org/10.1002/14651858.CD009753.pub2] [PMID: 27849333]
[21]
Fournier, N.; Tuloup-Minguez, V.; Pourci, M.L.; Thérond, P.; Jullian, J.C.; Wien, F.; Leroy, M.; Dal-longeville, J.; Paul, J.L.; Leroy, A. Fibrate treatment induced quantitative and qualitative HDL chang-es associated with an increase of SR-BI cholesterol efflux capacities in rabbits. Biochimie, 2013, 95(6), 1278-1287.
[http://dx.doi.org/10.1016/j.biochi.2013.02.001] [PMID: 23410672]
[22]
Tall, A.R.; Thomas, D.G.; Gonzalez-Cabodevilla, A.G.; Goldberg, I.J. Addressing dyslipidemic risk beyond LDL-cholesterol. J. Clin. Invest., 2022, 132(1), e148559.
[http://dx.doi.org/10.1172/JCI148559] [PMID: 34981790]
[23]
Fiévet, C.; Staels, B. Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr. Opin. Lipidol., 2009, 20(6), 505-511.
[http://dx.doi.org/10.1097/MOL.0b013e328332e9ef] [PMID: 19829109]
[24]
Norata, G.D.; Grigore, L.; Raselli, S.; Redaelli, L.; Hamsten, A.; Maggi, F.; Eriksson, P.; Catapano, A.L. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: Molecular mechanisms and gene expression studies. Atherosclerosis, 2007, 193(2), 321-327.
[http://dx.doi.org/10.1016/j.atherosclerosis.2006.09.015] [PMID: 17055512]
[25]
Wang, D.; Liu, B.; Tao, W.; Hao, Z.; Liu, M. Fibrates for secondary prevention of cardiovascular dis-ease and stroke. Cochrane Database Syst. Rev., 2015, 2015(10), CD009580.
[http://dx.doi.org/10.1002/14651858.CD009580.pub2] [PMID: 26497361]
[26]
Urizar, N.L.; Moore, D.D. GUGULIPID: A natural cholesterol-lowering agent. Annu. Rev. Nutr., 2003, 23(1), 303-313.
[http://dx.doi.org/10.1146/annurev.nutr.23.011702.073102] [PMID: 12626688]
[27]
Bays, H.E.; Ballantyne, C.M.; Kastelein, J.J.; Isaacsohn, J.L.; Braeckman, R.A.; Soni, P.N. Eicosapen-taenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Ex-tension [MARINE] trial). Am. J. Cardiol., 2011, 108(5), 682-690.
[http://dx.doi.org/10.1016/j.amjcard.2011.04.015] [PMID: 21683321]
[28]
King, A.J.; Segreti, J.A.; Larson, K.J.; Souers, A.J.; Kym, P.R.; Reilly, R.M.; Zhao, G.; Mittelstadt, S.W.; Cox, B.F. Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster. J. Pharmacol. Exp. Ther., 2009, 330(2), 526-531.
[http://dx.doi.org/10.1124/jpet.109.154047] [PMID: 19478132]

Rights & Permissions Print Cite
Article Metrics
28
1
© 2024 Bentham Science Publishers | Privacy Policy